Stocktoria
SELLAS Life Sciences Group, Inc. SLS
SELLAS Life Sciences Group, Inc. (SLS) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the grey zone. It pays a dividend yielding 0.02% (safety: no dividend).
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.87 |
| Retained earnings / assets | -3.51 |
| EBIT / assets | -0.361 |
| Equity / liabilities | 9.482 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SLS | SELLAS Life Sciences Group, Inc. | 2/9 | 1.8 | — | — |
| JNJ | JOHNSON & JOHNSON | 4/9 | — | 22.9 | +6% |
| LLY | ELI LILLY & Co | 7/9 | — | 55.1 | +44.7% |
| MRK | Merck & Co., Inc. | 4/9 | — | 17.4 | +1.3% |
| PFE | PFIZER INC | 4/9 | — | 17.8 | -1.6% |
| ABBV | AbbVie Inc. | 7/9 | -0.34 | 105.9 | +8.6% |
| BMY | BRISTOL MYERS SQUIBB CO | 7/9 | — | 16.7 | -0.2% |
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
FAQ
Is SLS financially healthy?
SELLAS Life Sciences Group, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does SLS pay a dividend, and is it safe?
Yes. SELLAS Life Sciences Group, Inc. pays a dividend yielding about 0.02% with a None payout ratio, rated “no dividend” for safety.
How profitable is SLS?
In FY2025, SELLAS Life Sciences Group, Inc. had a return on equity of -37.9%.
What is the analyst price target for SLS?
The average Wall-Street price target for SELLAS Life Sciences Group, Inc. is $10.00, about 15.0% below the recent price, from 2 analysts.
Is SLS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on SELLAS Life Sciences Group, Inc.: a Piotroski F-score of 2/9, an Altman Z″ in the grey zone, a dividend yield of 0.02%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.